Outlook Therapeutics (OTLK) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zura Bio (ZURA) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 74.4% versus a loss of 79.3%. Outlook Therapeutics is the larger company by market cap ($94.9 million vs $89.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | ZURA |
|---|---|---|
| Share price | $0.39 | $0.9305 |
| Market cap | $94.94M | $89.63M |
| 1-day change | -2.74% | -2.30% |
| YTD return | -75.32% | -82.24% |
| 1-year return | -79.26% | -74.37% |
| 5-year return | -98.58% | — |
| EPS (TTM) | $-0.70 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.41M | — |
| Net income (latest FY) | $-62.42M | $-68.65M |
| Gross margin | 4.05% | — |
| Operating margin | -4744.25% | — |
| Net margin | -4416.22% | — |
| 52-week high | $2.54 | $7.44 |
| 52-week low | $0.161 | $0.919 |
| Distance from 52-week high | -84.63% | -87.49% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1189.74% | +759.75% |
| Average volume | 4.60M | 4.47M |
| Shares outstanding | 243.45M | 96.33M |
| Employees | 17 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
OTLK vs ZURA FAQ
Which is bigger, Outlook Therapeutics or Zura Bio?
Outlook Therapeutics (OTLK) is larger, with a market capitalization of $94.94M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, OTLK or ZURA?
ZURA returned -74.37% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Outlook Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.